524731 — Jenburkt Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMicro CapHigh Flyer

Annual income statement for Jenburkt Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,240	1,367	1,420	1,517	1,687
Cost of Revenue
Gross Profit	913	1,022	1,101	1,202	1,364
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	986	1,086	1,112	1,140	1,321
Operating Profit	254	281	308	377	367
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	299	329	352	439	465
Provision for Income Taxes
Net Income After Taxes	223	246	260	321	347
Net Income Before Extraordinary Items
Net Income	223	246	260	321	347
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	223	246	260	321	347
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	48.3	55.7	58.9	72.6	85.4
Dividends per Share